Combination Therapy

FDA Clears Padcev Plus Keytruda Regimens as Perioperative Option for Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

The approval is backed by phase 3 EV-303 results showing superior survival compared with cystectomy alone.